Prescription Status For Pseudoephedrine In U.K. Put On Hold For Two Years
This article was originally published in The Tan Sheet
Executive Summary
The British health authority will move pseudoephedrine- and ephedrine-containing OTCs to prescription-only status in two years unless the risk of the products' use in the illicit manufacturing of methamphetamine decreases by that time
You may also be interested in...
U.K. Industry Asks For More Time To Prepare For Limits On OTC PSE Sales
U.K. drug firms say the country's regulatory agency is not allowing enough time to comply with an order banning nonprescription access to product packages with more than 720 mg of pseudoephedrine beginning April 1
State Pseudoephedrine Proposals Go Above, Beyond Combat Meth Act
The National Association of Chain Drug Stores has "concerns" with state bills proposing the establishment of real-time electronic repositories to monitor and limit pseudoephedrine sales, according to the trade group
U.K. Proposes Prescription-Only Status For Pseudoephedrine Products
The U.K. Medicines and Healthcare products Regulatory Agency is proposing prescription status for pseudoephedrine- and ephedrine-containing drugs in order to prevent the illegal manufacture of methamphetamine